Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.

ABSTRACT:

Objective

To provide a complete toxicity profile, toxicity spectrum, and a safety ranking of immune checkpoint inhibitor (ICI) drugs for treatment of cancer.

Design

Systematic review and network meta-analysis.

Data sources

Electronic databases (PubMed, Embase, Cochrane Library, and Web of Science) were systematically searched to include relevant studies published in English between January 2007 and February 2018.

Review methods

Only head-to-head phase II and III randomised controlled trials comparing any two or three of the following treatments or different doses of the same ICI drug were included: nivolumab, pembrolizumab, ipilimumab, tremelimumab, atezolizumab, conventional therapy (chemotherapy, targeted therapy, and their combinations), two ICI drugs, or on

SUBMITTER: Xu C 

PROVIDER: S-EPMC6222274 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature